| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1 |
| Entrez GeneID | 3716 |
| clone | 12G8 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthetic peptide conjugated to KLH. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于JAK1抗体的模拟参考文献示例，格式包含文献名称、作者及简要摘要：
---
1. **"A Novel Monoclonal Antibody Targeting JAK1 Suppresses Inflammatory Signaling in Autoimmune Diseases"**
*作者：Zhang L, et al.*
**摘要**：本研究开发了一种新型抗JAK1单克隆抗体，证实其在体外和小鼠类风湿性关节炎模型中显著抑制促炎细胞因子信号传导，提示其作为潜在治疗药物的价值。
2. **"JAK1-Specific Antibody Reveals Differential Expression Patterns in Solid Tumors"**
*作者：Gupta R, et al.*
**摘要**：通过免疫组化技术，利用高特异性JAK1抗体分析多种实体瘤组织，发现JAK1在黑色素瘤和肺癌中高表达，并与肿瘤侵袭性相关。
3. **"Structural and Functional Characterization of a Neutralizing Anti-JAK1 Antibody for Therapeutic Applications"**
*作者：Sato K, et al.*
**摘要**：结合冷冻电镜和功能实验，解析了一种中和性抗JAK1抗体的作用机制，证明其通过阻断JAK1-STAT3相互作用抑制肿瘤生长。
4. **"Development of a Phospho-Specific JAK1 Antibody for Signaling Pathway Analysis"**
*作者：Müller S, et al.*
**摘要**：研发出一种磷酸化位点特异的JAK1抗体，用于检测JAK1激活状态，为研究JAK-STAT信号通路在炎症和癌症中的动态调控提供了工具。
---
**注**：以上文献为示例，并非真实存在的论文。实际研究中建议通过PubMed、Web of Science等数据库检索具体文献。
JAK1 (Janus kinase 1) is a tyrosine kinase critical for cytokine receptor signaling, playing a key role in the JAK-STAT pathway. It mediates immune regulation, inflammation, and hematopoiesis by transducing signals from cytokines (e.g., interferons, interleukins) and growth factors. Dysregulation of JAK1 is linked to autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease), cancers, and allergic disorders.
JAK1 antibodies are tools used to study its expression, activation, and interactions in research settings, employing techniques like Western blotting, immunohistochemistry, or flow cytometry. Therapeutically, "JAK1 antibodies" often refer to inhibitors (small molecules or biologics) targeting JAK1 activity. Drugs like upadacitinib selectively inhibit JAK1 to block pro-inflammatory signaling, offering treatments for conditions such as atopic dermatitis or psoriasis. However, JAK1's broad role in immunity raises safety concerns, including infection risks. Current research focuses on optimizing selectivity to minimize off-target effects while maintaining efficacy. These advancements highlight JAK1's dual significance as a biomarker in disease mechanisms and a therapeutic target in precision medicine.
×
